AN2 Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 11, 2026

ANTX$4.00+1.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and per share amounts)

	March 31,	December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$53,487	$19,941
Short-term investments	31,801	38,060
Prepaid expenses and other current assets	2,203	1,936
Total current assets	87,491	59,937
Long-term investments	—	2,013
Total assets	$87,491	$61,950
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$2,615	$3,021
Accrued compensation	613	2,418
Accrued liabilities	1,767	2,052
Other current liabilities	567	1,229
Total current liabilities	5,562	8,720
Other non-current liabilities	170	170
Total liabilities	5,732	8,890
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025	—	—
Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 35,985,599 and 27,413,171 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	—	—
Additional paid-in capital	332,742	293,953
Accumulated other comprehensive (loss) gain	(5)	57
Accumulated deficit	(250,978)	(240,950)
Total stockholders’ equity	81,759	53,060
Total liabilities and stockholders’ equity	$87,491	$61,950

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.